Nyrada AGM 2021 Chairman’s Address

“Looking forward, we expect Phase I studies for both the Cholesterol-Lowering and Brain Injury Programs will commence in the second half of next year, following the completion of safety pharmacology and toxicology studies. The Phase I studies will be run in Australia.
Nyrada remains in a sound financial position having completed an A$11.5M capital raise in the second half of the financial year, which will fund a Phase I study for each of our Cholesterol-Lowering and Brain Injury drug candidates.”

John Moore Chairman, Nyrada Inc